MIC determination of critical important backup antibiotics used for clinically important non-fermenting pathogens
In recent years, there has been a dramatic increase in multi-drug resistance (MDR) amongst gram-negative pathogens like Pseudomonas aeruginosa, Acinetobacter baumannii and other non-fermenting organisms. This has impacted the treatment of both hospital and community acquired infections. Therefore, accurate and reliable MIC determination is crucial for a successful antimicrobial therapy.
The routine MIC plate MICRONAUT-S Pseudomonas MIC provides an extended spectrum of standard and critical important backup antibiotics used for treatment of infections caused by multi-drug resistant non-fermenting pathogens. It enables MIC determination of antibiotics like piperacillin-tazobactam, ceftazidime-avibactam, ceftolozane-tazobactam, meropenem, tigecyclin and colistin in a single test run. MIC values are interpreted according to currently valid EUCAST breakpoints.
MIC plate for AST of multi-drug resistant non-fermenting bacteria (MDR phenotype) The MICRONAUT-S Pseudomonas MIC test plate offers a range of features and benefits relating to the phenotypic quantification of MIC values for critically important backup antibiotics used for treatment of bacterial infections caused by non-fermenting bacteria.
AST is carried out by broth microdilution method
Resistance determination of clinically relevant non-fermenting organisms (Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and other non-fermenters) against antibiotics and antibiotic combinations
AST for highly effective and critically important backup antibiotics and antibiotic combinations like piperacillin-tazobactam, ceftazidime-avibactam, ceftolozane-tazobactam or tigecycline in a single test run
Accurate and reliable AST for colistin
Analysis and interpretation of MIC values after visual or automated reading according to EUCAST standard
Antibiotics Including critically important antibiotics like ceftazidime-avibactam, ceftolozane-tazobactam and colistin, showing good antimicrobial efficacy against gram-negative bacteria.